Payment overview · 2025
General Payments
$5,187.66
92 reported records · 22 companies
Healthcare provider profile · identity verified
Philipp Alexander Wiesner, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SPRINGFIELD, MO · NPI 1609162817
Verified facts
What the public records show
CMS Open Payments records show Philipp Alexander Wiesner, M.D. received $5,187.66 in general payments during 2025 across 92 reported records.
Boston Scientific Corporation accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1233 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1233 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,021.53 | 19.7% | 23 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $931.67 | 18.0% | 17 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $804.18 | 15.5% | 8 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $574.26 | 11.1% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $503.93 | 9.7% | 7 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $197.90 | 3.8% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$178.94 | 3.5% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $177.94 | 3.4% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $138.40 | 2.7% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $127.18 | 2.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $123.62 | 2.4% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $100.80 | 1.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.14 | 1.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.46 | 1.0% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $37.34 | 0.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.59 | 0.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $22.75 | 0.4% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $18.67 | 0.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.10 | 0.3% | 1 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $17.09 | 0.3% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $16.50 | 0.3% | 1 | 2025 |
| Nipro Medical Corporation | Unresolved — no canonical attribution shown | $15.67 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,187.66 | 92 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $712.66 | 14 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $593.70 | 14 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $322.09 | 8 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $255.60 | 4 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $228.71 | 2 | 2025 |
Source payment records
|
|||||
| TURNPIKE Normalized: turnpike |
Device | Teleflex LLC | $223.28 | 3 | 2025 |
Source payment records
|
|||||
| MANTA Normalized: manta |
Device | Teleflex LLC | $206.86 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $197.90 | 3 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $178.94 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $177.94 | 1 | 2025 |
Source payment records
|
|||||
| TRAPLINER Normalized: trapliner |
Device | Teleflex LLC | $144.12 | 1 | 2025 |
Source payment records
|
|||||
| HEARTRAIL Normalized: heartrail |
Device | Terumo Medical Corporation | $138.40 | 2 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $138.40 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $127.18 | 1 | 2025 |
Source payment records
|
|||||
| ELCA Normalized: elca |
Device | Philips North America LLC | $123.62 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $113.22 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $105.79 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $105.74 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $100.80 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $76.21 | 4 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $53.46 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.65 | 3 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $37.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.59 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Hemodialysis System Normalized: hemodialysis system |
Device | Nipro Medical Corporation | $15.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1233 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 23 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1233 | 262 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1233 | 262 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 2187 | 682 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1836 | 561 |
| Eliquis | Apixaban | 1233 | 262 |
| Spironolactone | Spironolactone | 1095 | 333 |
| Amlodipine Besylate | Amlodipine Besylate | 1049 | 360 |
| Clopidogrel | Clopidogrel Bisulfate | 993 | 329 |
| Furosemide | Furosemide | 904 | 305 |
| Lisinopril | Lisinopril | 900 | 296 |
| Carvedilol | Carvedilol | 880 | 256 |
| Losartan Potassium | Losartan Potassium | 809 | 256 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 684 | 216 |
| Xarelto | Rivaroxaban | 469 | 90 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 451 | 150 |
| Warfarin Sodium | Warfarin Sodium | 428 | 106 |
| Hydrochlorothiazide | Hydrochlorothiazide | 409 | 131 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 387 | 122 |
| Valsartan | Valsartan | 356 | 123 |
| Potassium Chloride | Potassium Chloride | 353 | 116 |
| Repatha Sureclick | Evolocumab | 223 | 34 |
| Ezetimibe | Ezetimibe | 214 | 66 |
| Entresto | Sacubitril/Valsartan | 211 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 77 |
| Nitroglycerin | Nitroglycerin | 172 | 109 |
| Ranolazine Er | Ranolazine | 154 | 43 |
| Bumetanide | Bumetanide | 146 | 39 |
| Simvastatin | Simvastatin | 133 | 40 |
| Nifedipine Er | Nifedipine | 126 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 44 |
| Amiodarone Hcl | Amiodarone Hcl | 102 | 40 |
| Farxiga | Dapagliflozin Propanediol | 101 | 23 |
| Torsemide | Torsemide | 87 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 74 | 26 |
| Irbesartan | Irbesartan | 73 | 23 |
| Sotalol | Sotalol Hcl | 71 | 18 |
| Repatha Syringe | Evolocumab | 63 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 57 | 21 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 49 | 16 |
| Praluent Pen | Alirocumab | 48 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 46 | 14 |
| Ramipril | Ramipril | 44 | 17 |
| Klor-Con M20 | Potassium Chloride | 41 | 12 |
| Flecainide Acetate | Flecainide Acetate | 39 | 11 |
| Atenolol | Atenolol | 37 | 14 |
| Cartia Xt | Diltiazem Hcl | 37 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | 14 |
| Digoxin | Digoxin | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 19 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 12 |
| Jardiance | Empagliflozin | 22 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Eplerenone | Eplerenone | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,187.66 · 92 records | Boston Scientific Corporation | AVVIGO Guidance System, Asahi Coronary Wires, Assure WCD, Barostim Neo System, COREVALVE EVOLUT R, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELCA, ELIQUIS, ESPRIT, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FFRct, GORE VIABAHN VBX Balloon Expandable Endo, HEARTRAIL, Hemodialysis System, INSPIRE, LOKELMA, LUTONIX Drug Coated Balloon, MANTA, METACROSS OTW, MITRACLIP, PAXLOVID, REPATHA, SAPIEN 3 Ultra RESILIA, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRAPLINER, TRICLIP, TURNPIKE, WATCHMAN Access System, WATCHMAN FLX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error